ReviewTurkish journal of urology2014
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.
Review in Turkish journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Pilot study of dual-arm absolute quantification of miR-130a and miR-365a in plasma and urine reveals 3p/5p strand-ratio shifts in prostate cancer.Scientific reports · 2026Article
- hsa-circKLK3-25 promotes epithelial-mesenchymal transition and malignant progression of prostate cancer through the JNK/ERK signaling pathway.American journal of cancer research · 2026Article
- Comparative Analysis of miRNA Expression 106a-5p and 375-3p and Proteins ERK1/2, p38, β-Catenin and E-Cadherin in Prostate Cancer and Benign Prostatic Hyperplasia.Journal of cellular and molecular medicine · 2025Article
- Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Multiplexed quantitative proteomics in prostate cancer biomarker development.Advances in cancer research · 2024Review
- Machine learning-based prediction model and visual interpretation for prostate cancer.BMC urology · 2023Article
- Comparison of Serum Gamma Glutamyl Transferase Levels between Prostate Cancer Patients and Their Healthy Peers.Iranian journal of public health · 2023Article
- Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy.Frontiers in surgery · 2023Article
- Review
- Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.Journal of personalized medicine · 2021Review
- Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.Journal of personalized medicine · 2021Review
- Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.Indian journal of clinical biochemistry : IJCB · 2021Article
- Pseudouridine as a novel biomarker in prostate cancer.Urologic oncology · 2021Review
- Diagnostic benefits of mindin as a prostate cancer biomarker: Dijagnostičke prednosti mindina kao biomarkera raka prostate.Journal of medical biochemistry · 2020Article
- Bioconjugated, Single-Use Biosensor for the Detection of Biomarkers of Prostate Cancer.ACS omega · 2018Article
- TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.Turkish journal of urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, prostate- specific antigen (PSA) is the most common oncological marker used for prostate cancer screening. However, high levels of PSA in benign prostatic hyperplasia and prostatitis decrease the specificity of PSA as a cancer marker. To increase the specificity of PSA, PSA derivatives and PSA kinetics have been used. However, these new techniques were not able to increase the diagnostic specificity for prostate cancer. Therefore, the search for new molecules and derivatives of PSA continues. With the aim of increasing the specificity of prostate cancer diagnosis, proPSA and the Prostate Health Index have been introduced. In this review, the roles of PSA, PSA derivatives, proPSA and the Prostate Health Index in Prostate Cancer diagnosis are examined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.